A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects With Progressive Multiple Sclerosis
Phase of Trial: Phase II
Latest Information Update: 30 Aug 2017
At a glance
- Drugs Ibudilast (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms SPRINT-MS
- Sponsors MediciNova
- 30 Aug 2017 Top-line results from this trial will be presented at the 7th Joint ECTRIMS - ACTRIMS Meeting according to a MediciNova media release.
- 10 Aug 2017 Status changed from active, no longer recruiting to completed.
- 28 Apr 2017 Results (n=261) presented at the 69th Annual Meeting of the American Academy of Neurology